Update Regarding Variant Strains of SARS-CoV-2
United States public health agencies regularly monitor SARS-CoV-2 genetic lineages through epidemiological investigations, laboratory studies and genetic sequence-based surveillance. The US government SARS-CoV-2 Interagency Group (SIG) has designated the following classes of SARS-CoV-2 variants of public health interest: Variants of High Consequence (VOHC), Variants of Concern (VOC), Variants of Interest (VOI), and Variants Being Monitored (VBM).*
Rheonix has conducted analysis of the potential impact of all classes of variants being monitored and has determined that they should not impact performance of the Rheonix COVID-19™ MDx assay.
Rheonix continually evaluates publicly available SARS-CoV-2 genetic sequences to identify the potential impact of variants on our assay performance. Our assessments indicate that all characterized SARS-CoV-2 variants currently being monitored should be detected by the Rheonix COVID-19 MDx assay, as summarized in the table below. We will continue to monitor the available sequences weekly to identify any potentially concerning mutations as they emerge.
|WHO Label||PANGO Lineage||CDC Variant Classification*||Impact to Rheonix COVID-19™ MDx Assay|
|Delta||B.1.617.2 and AY lineages||VOC||No impact|
|Omicron||B.1.1.529, including BA lineages||VOC||No impact|
|Alpha||B.1.1.7 and Q lineages||VBM||No impact|
|Beta||B.1.351 and descendent lineages||VBM||No impact|
|Gamma||P.1 and descendent lineages||VBM||No impact|
|Mu||B.1.621, B.1.621.1||VBM||No impact|
*Source: SARS-CoV-2 Variants of Concern | CDC